Compare MAMA & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MAMA | PGEN |
|---|---|---|
| Founded | 2010 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 474.8M | 1.5B |
| IPO Year | N/A | N/A |
| Metric | MAMA | PGEN |
|---|---|---|
| Price | $12.66 | $4.51 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $17.00 | $7.67 |
| AVG Volume (30 Days) | 582.9K | ★ 5.4M |
| Earning Date | 12-08-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 41.91 | N/A |
| EPS | ★ 0.12 | N/A |
| Revenue | ★ $151,312,000.00 | $6,309,000.00 |
| Revenue This Year | $39.64 | $342.78 |
| Revenue Next Year | $28.85 | $478.46 |
| P/E Ratio | $105.38 | ★ N/A |
| Revenue Growth | 29.92 | ★ 59.20 |
| 52 Week Low | $5.50 | $1.05 |
| 52 Week High | $14.97 | $5.23 |
| Indicator | MAMA | PGEN |
|---|---|---|
| Relative Strength Index (RSI) | 47.47 | 56.95 |
| Support Level | $12.48 | $4.01 |
| Resistance Level | $13.95 | $4.95 |
| Average True Range (ATR) | 0.55 | 0.32 |
| MACD | -0.22 | 0.05 |
| Stochastic Oscillator | 6.83 | 55.71 |
Mama's Creations Inc is a marketer and manufacturer of fresh deli-prepared foods, found in grocery, mass, club, and convenience stores nationally. The company's broad product portfolio, born from a rich history in Italian foods, now consists of a variety of high-quality, fresh, clean, and easy-to-prepare foods to address the needs of both consumers and retailers. The brand of the company includes Mama's Creations, Mama's Mancini's, The Olive Branch, Creative Salads, and others.
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.